vs
Andersons, Inc.（ANDE）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Andersons, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.6倍（$329.5M vs $207.3M），Andersons, Inc.净利率更高（20.5% vs -62.0%，领先82.5%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -2.4%），Andersons, Inc.自由现金流更多（$-77.1M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -1.8%）
安德森公司（The Andersons, Inc.）是1947年成立的美国农业企业，总部位于俄亥俄州莫米。公司起源于1940年代服务粮食行业的安德森货运站，是深耕农业领域的多元化企业，业务覆盖大宗商品贸易、可再生能源以及植物营养板块。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ANDE vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $329.5M | $207.3M |
| 净利润 | $67.4M | $-128.6M |
| 毛利率 | 70.3% | — |
| 营业利润率 | 26.6% | -54.7% |
| 净利率 | 20.5% | -62.0% |
| 营收同比 | -2.4% | 25.9% |
| 净利润同比 | 49.6% | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $329.5M | $207.3M | ||
| Q3 25 | $295.8M | $159.9M | ||
| Q2 25 | $535.0M | $166.5M | ||
| Q1 25 | $370.8M | $139.3M | ||
| Q4 24 | $337.5M | $164.6M | ||
| Q3 24 | $231.9M | $139.5M | ||
| Q2 24 | $492.5M | $147.0M | ||
| Q1 24 | $341.4M | $108.8M |
| Q4 25 | $67.4M | $-128.6M | ||
| Q3 25 | $20.1M | $-180.4M | ||
| Q2 25 | $7.9M | $-115.0M | ||
| Q1 25 | $284.0K | $-151.1M | ||
| Q4 24 | $45.1M | $-133.2M | ||
| Q3 24 | $27.4M | $-133.5M | ||
| Q2 24 | $36.0M | $-131.6M | ||
| Q1 24 | $5.6M | $-170.7M |
| Q4 25 | 70.3% | — | ||
| Q3 25 | 57.8% | — | ||
| Q2 25 | 29.6% | — | ||
| Q1 25 | 41.2% | — | ||
| Q4 24 | 63.1% | — | ||
| Q3 24 | 76.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 37.6% | — |
| Q4 25 | 26.6% | -54.7% | ||
| Q3 25 | 8.7% | -106.9% | ||
| Q2 25 | 4.6% | -64.8% | ||
| Q1 25 | 0.9% | -102.6% | ||
| Q4 24 | 19.9% | -74.3% | ||
| Q3 24 | 26.8% | -94.6% | ||
| Q2 24 | 11.6% | -79.1% | ||
| Q1 24 | 4.1% | -151.9% |
| Q4 25 | 20.5% | -62.0% | ||
| Q3 25 | 6.8% | -112.8% | ||
| Q2 25 | 1.5% | -69.0% | ||
| Q1 25 | 0.1% | -108.5% | ||
| Q4 24 | 13.4% | -80.9% | ||
| Q3 24 | 11.8% | -95.7% | ||
| Q2 24 | 7.3% | -89.5% | ||
| Q1 24 | 1.6% | -156.8% |
| Q4 25 | — | $-1.28 | ||
| Q3 25 | $0.59 | $-1.81 | ||
| Q2 25 | $0.23 | $-1.17 | ||
| Q1 25 | $0.01 | $-1.57 | ||
| Q4 24 | $1.31 | $-1.34 | ||
| Q3 24 | $0.80 | $-1.40 | ||
| Q2 24 | $1.05 | $-1.52 | ||
| Q1 24 | $0.16 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.3M | $421.0M |
| 总债务越低越好 | $560.0M | — |
| 股东权益账面价值 | $1.2B | $-80.0M |
| 总资产 | $3.7B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.45× | — |
8季度趋势，按日历期对齐
| Q4 25 | $98.3M | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | $561.8M | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $560.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $608.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $-80.0M | ||
| Q3 25 | $1.2B | $9.2M | ||
| Q2 25 | $1.4B | $151.3M | ||
| Q1 25 | $1.4B | $144.2M | ||
| Q4 24 | $1.4B | $255.0M | ||
| Q3 24 | $1.3B | $346.8M | ||
| Q2 24 | $1.3B | $432.4M | ||
| Q1 24 | $1.3B | $140.3M |
| Q4 25 | $3.7B | $1.5B | ||
| Q3 25 | $3.3B | $1.2B | ||
| Q2 25 | $3.4B | $1.3B | ||
| Q1 25 | $3.8B | $1.3B | ||
| Q4 24 | $4.1B | $1.5B | ||
| Q3 24 | $3.4B | $1.5B | ||
| Q2 24 | $3.3B | $1.6B | ||
| Q1 24 | $3.3B | $1.3B |
| Q4 25 | 0.45× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.2M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-77.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | -23.4% | -48.6% |
| 资本支出强度资本支出/营收 | 21.5% | 0.5% |
| 现金转化率经营现金流/净利润 | -0.09× | — |
| 过去12个月自由现金流最近4个季度 | $-56.1M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-6.2M | $-99.8M | ||
| Q3 25 | $233.9M | $-91.4M | ||
| Q2 25 | $299.3M | $-108.3M | ||
| Q1 25 | $-350.0M | $-166.5M | ||
| Q4 24 | $268.8M | $-79.3M | ||
| Q3 24 | $-2.1M | $-67.0M | ||
| Q2 24 | $304.4M | $-77.0M | ||
| Q1 24 | $-239.6M | $-190.7M |
| Q4 25 | $-77.1M | $-100.8M | ||
| Q3 25 | $167.0M | $-92.7M | ||
| Q2 25 | $250.5M | $-110.7M | ||
| Q1 25 | $-396.6M | $-167.8M | ||
| Q4 24 | $212.9M | $-79.5M | ||
| Q3 24 | $-40.0M | $-68.6M | ||
| Q2 24 | $275.8M | $-79.0M | ||
| Q1 24 | $-266.4M | $-193.9M |
| Q4 25 | -23.4% | -48.6% | ||
| Q3 25 | 56.5% | -58.0% | ||
| Q2 25 | 46.8% | -66.5% | ||
| Q1 25 | -106.9% | -120.5% | ||
| Q4 24 | 63.1% | -48.3% | ||
| Q3 24 | -17.2% | -49.2% | ||
| Q2 24 | 56.0% | -53.7% | ||
| Q1 24 | -78.0% | -178.2% |
| Q4 25 | 21.5% | 0.5% | ||
| Q3 25 | 22.6% | 0.8% | ||
| Q2 25 | 9.1% | 1.5% | ||
| Q1 25 | 12.6% | 1.0% | ||
| Q4 24 | 16.6% | 0.1% | ||
| Q3 24 | 16.3% | 1.2% | ||
| Q2 24 | 5.8% | 1.4% | ||
| Q1 24 | 7.8% | 3.0% |
| Q4 25 | -0.09× | — | ||
| Q3 25 | 11.61× | — | ||
| Q2 25 | 38.10× | — | ||
| Q1 25 | -1232.46× | — | ||
| Q4 24 | 5.96× | — | ||
| Q3 24 | -0.08× | — | ||
| Q2 24 | 8.46× | — | ||
| Q1 24 | -42.94× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANDE
| Specialty And Primary Nutrients | $137.1M | 42% |
| Premium Ingredients | $66.1M | 20% |
| Segment Reporting Reconciling Item Other | $63.2M | 19% |
| Other | $63.1M | 19% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
